Home > Research > Publications & Outputs > Reverse engineering of Alzheimer's disease base...

Links

Text available via DOI:

View graph of relations

Reverse engineering of Alzheimer's disease based on biomarker pathways analysis

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Reverse engineering of Alzheimer's disease based on biomarker pathways analysis. / Richens, Joanna L.; Morgan, Kevin; O'Shea, Paul.
In: Neurobiology of Aging, Vol. 35, No. 9, 09.2014, p. 2029-2038.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Richens JL, Morgan K, O'Shea P. Reverse engineering of Alzheimer's disease based on biomarker pathways analysis. Neurobiology of Aging. 2014 Sept;35(9):2029-2038. Epub 2014 Mar 2. doi: 10.1016/j.neurobiolaging.2014.02.024

Author

Richens, Joanna L. ; Morgan, Kevin ; O'Shea, Paul. / Reverse engineering of Alzheimer's disease based on biomarker pathways analysis. In: Neurobiology of Aging. 2014 ; Vol. 35, No. 9. pp. 2029-2038.

Bibtex

@article{41ed920076ad46ba9f55cdd27fa39d1d,
title = "Reverse engineering of Alzheimer's disease based on biomarker pathways analysis",
abstract = "Alzheimer's disease (AD) poses an increasingly profound problem to society, yet progress toward a genuine understanding of the disease remains worryingly slow. Perhaps, the most outstanding problem with the biology of AD is the question of its mechanistic origins, that is, it remains unclear wherein the molecular failures occur that underlie the disease. We demonstrate how molecular biomarkers could help define the nature of AD in terms of the early biochemical events that correlate with disease progression. We use a novel panel of biomolecules that appears in cerebrospinal fluid of AD patients. As changes in the relative abundance of these molecular markers are associated with progression to AD from mild cognitive impairment, we make the assumption that by tracking their origins we can identify the biochemical conditions that predispose their presence and consequently cause the onset of AD. We couple these protein markers with an analysis of a series of genetic factors and together this hypothesis essentially allows us to redefine AD in terms of the molecular pathways that underlie the disease.",
keywords = "Alzheimer's disease, Dementia, Biomarkers, Pathways analysis",
author = "Richens, {Joanna L.} and Kevin Morgan and Paul O'Shea",
year = "2014",
month = sep,
doi = "10.1016/j.neurobiolaging.2014.02.024",
language = "English",
volume = "35",
pages = "2029--2038",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Reverse engineering of Alzheimer's disease based on biomarker pathways analysis

AU - Richens, Joanna L.

AU - Morgan, Kevin

AU - O'Shea, Paul

PY - 2014/9

Y1 - 2014/9

N2 - Alzheimer's disease (AD) poses an increasingly profound problem to society, yet progress toward a genuine understanding of the disease remains worryingly slow. Perhaps, the most outstanding problem with the biology of AD is the question of its mechanistic origins, that is, it remains unclear wherein the molecular failures occur that underlie the disease. We demonstrate how molecular biomarkers could help define the nature of AD in terms of the early biochemical events that correlate with disease progression. We use a novel panel of biomolecules that appears in cerebrospinal fluid of AD patients. As changes in the relative abundance of these molecular markers are associated with progression to AD from mild cognitive impairment, we make the assumption that by tracking their origins we can identify the biochemical conditions that predispose their presence and consequently cause the onset of AD. We couple these protein markers with an analysis of a series of genetic factors and together this hypothesis essentially allows us to redefine AD in terms of the molecular pathways that underlie the disease.

AB - Alzheimer's disease (AD) poses an increasingly profound problem to society, yet progress toward a genuine understanding of the disease remains worryingly slow. Perhaps, the most outstanding problem with the biology of AD is the question of its mechanistic origins, that is, it remains unclear wherein the molecular failures occur that underlie the disease. We demonstrate how molecular biomarkers could help define the nature of AD in terms of the early biochemical events that correlate with disease progression. We use a novel panel of biomolecules that appears in cerebrospinal fluid of AD patients. As changes in the relative abundance of these molecular markers are associated with progression to AD from mild cognitive impairment, we make the assumption that by tracking their origins we can identify the biochemical conditions that predispose their presence and consequently cause the onset of AD. We couple these protein markers with an analysis of a series of genetic factors and together this hypothesis essentially allows us to redefine AD in terms of the molecular pathways that underlie the disease.

KW - Alzheimer's disease

KW - Dementia

KW - Biomarkers

KW - Pathways analysis

U2 - 10.1016/j.neurobiolaging.2014.02.024

DO - 10.1016/j.neurobiolaging.2014.02.024

M3 - Journal article

VL - 35

SP - 2029

EP - 2038

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 9

ER -